## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE:	Application	of Matthew	Spencer	COLLINS
--------	-------------	------------	---------	---------

Serial No.: To be assigned

Art Unit:

Filing Date: Concurrently herewith

Examiner:

For: A Fluid Dispensing Device

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- [X] Copies of the references listed on the attached form PTO-1449 as item nos. 6, and 9-11 are enclosed
  [] Copies of the references were submitted in parent application Serial No. (37 CFR 1.98(d))
  [X] A copy of the International Search Report which issued on International Application No.
- PCT/EP2003/008497 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 as item nos. 5, 7 and 8 and Amplicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. [X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last, 37 CFR 1.97(b).
  - OR
    [] The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.E.R. 1.114 (37 C.E.R. 1.190b)(41).
- B. [] The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
  - (1) a final action under § 1.113 or
  - (2) a notice of allowance under § 1.311,

whichever occurs first.

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [ ] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

## DT05 Rec CT/PT0 2 7 JAN 2005

C. [] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- [ ] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.

[ ] A duplicate copy of this paper is attached.

Respectfully Submitted,

James P. Riek
Attorney of Record
Registration No. 39.009

Date: January 27, 2005 GlaxoSmithKline

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8022

Facsimile: (919) 483-8022

10/523256

						5 Respect	PTO 27	
FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTORNEY D	OCK NO.	SERIAL NO.			
			PG4902USw		To be assigned			
					APPLICANT	1	£ 1	- 1 L
					Matthew Spence	er COLLINS		4 i
					FILING DATE		GROUP	
					Concurrently he	rewith	<u> </u>	pr.
			U.S. P	ATENT D	OCUMENTS			
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriate
/A.B./	1.	3,272,391	09/13/1966	MESHBERG			1	70
/A.B./	2.	4,771,769	09/20/1988	HEGEM/		, ,	1	in 1
/A.B./	3.	6,189,739	02/20/2001		IUCKMANN		9	TE 1
/A.B./	4.	6,315,165	11/13/2001	REGAN	TO CIENTE III	- : 1	7	10. I
/A.B./	5.	2002/008122	01/24/2002		R-PERTH et al.		11 11	9
/A.B./	٦.	2002/000122	01/24/2002	GIGLITE	C-1 LICITI CC MI.		1	20. 1
							4 +	7. 1
	ــــــــــــــــــــــــــــــــــــــ			ontinue on p	2200	<u> </u>	<del></del>	1-
					DOCUMENTS		·	
	_	Document	Publication	TATEN	DOCUMENTS		*	Translation
	l	Number	Date	1 .	Country	Class :	Subclass	Yes   No
/A.B./	6.	GB 2251898	07/22/1992	GB	Country	Ciass	Bubciass	12
/A.B./	7.	DE 19610456	09/18/1997	DE		; ;	<del>1</del> 11	ite.
/A.B./	8.	WO 00/18458	04/06/2000	WIPO			1 11	16i I
/A.B./	9.	FR 2807954	10/26/2001	FR		- :	7. 10	X (abstract)
/A.B./	10.	FR 2812826	02/15/2002	FR		: 1	9 8	X (abstract)
/A.B./	11.	WO 03/095007	11/20/2003	WIPO		<del>-                                    </del>	13 1	X (abstract)
////	11.	W O 03/093007	11/20/2003	WIFO			8 1	
				-			7	1.1
	_						1 1	14
	-			<del></del>		- 1	12	
		L		ontinue on 1		<u> </u>	<del>:</del>	
		OWNER BOOKS			Title, Journal-Da	. D M	han Etal	
		OTHER DOCUM	TEN 15 (Includi	ng Autnor,	Title, Journal-Da	te, Page Num		
	_						<u>}</u>	
	_						<del>ja</del>	13 1
		-				<del>-</del>		
							13 1	1 10
						1	t, i	Digital Control
								. 1 <sup>8</sup> /
							54	d;
	<u> </u>					<u>i</u>	C ;	***
						1	<u>r - </u>	<del></del>
						!		
		ļ				i	ii	. "
		I				- !	b s	
				Continue on	page		1 4	ile
	/Andrew Bainbridge/						CONSIDERE	
		al if citation conside						
citation if no	t in co	nformance and not	considered. Inclu	ide copy of	this form with next	communication	on to the appl	icant.

## BEST AVAILABLE COPY